Evaluation of safety and efficacy of PDxane® in comparison to Clexane® in prophylaxis of venous thromboembolism in Major Gynecology Surgeries

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090914002459N2

Enrollment

200

Registered

2018-06-10

Start date

2016-02-19

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous Thromboembolism fallowing major gynecology surgery. Embolism and thrombosis of unspecified artery

Interventions

Intervention 1: Intervention group 1 : Receiving an enoxaparin drug with the PDxane® brand to test the effects of thrombophilaxy and side effects. Intervention 2: Intervention group2: Receiving an eno

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Major Gynecology Surgeries Adult (aged 18 and more)

Exclusion criteria

Exclusion criteria: Having clinical symptoms of Venus thrombosis Having active bleeding or a high risk of bleeding History of thromboembolic diseases Malignancy Pregnancy Severe renal impairment Significant liver disease

Design outcomes

Primary

Measure	Time frame
Prevention of Venous Thromboembolism. Timepoint: 10 days after surgery. Method of measurement: History taking and clinical assessments.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammadreza Javadi

Tehran University of Medical Sciences

mrjavadi@tums.ac.ir+98 21 0218 4901

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026